Reuters logo
BRIEF-Galena Biopharma confirms regulatory pathway for GALE-401
December 28, 2016 / 12:19 PM / a year ago

BRIEF-Galena Biopharma confirms regulatory pathway for GALE-401

Dec 28 (Reuters) - Galena Biopharma Inc :

* Galena Biopharma confirms regulatory pathway for GALE-401 (anagrelide controlled release)

* “remain on track to initiate trial in Q2 of 2017”

* Galena Biopharma Inc- company expects to finalize phase 3 clinical trial protocol and initiate trial in Q2, 2017 for GALE-401

* Galena Biopharma Inc - company has confirmed regulatory pathway to advance GALE-401 into a pivotal, Phase 3 trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below